Becton, Dickinson and Company

Becton, Dickinson and Company Overview

Company Headquarters: New Jersey, US

Founded: 1897

Workforce: ~65,000

Company Working: Becton, Dickinson and Company (BD) is engaged in developing and manufacturing medical supplies, laboratory equipment, and diagnostic products. It operates in two segments, BD Medical and BD Life Sciences. Its life sciences segment offers products, such as liquid-based cytology systems, specimens, and blood collection products and systems, automated blood and tuberculosis culturing, molecular testing, rapid diagnostic assays, microbiology laboratory automation products, and fluorescence-activated cell sorters. Its medical segment comprises products, such as needle-free IV connectors and extension sets, peripheral IV and advanced peripheral catheters, acute dialysis catheters, vascular care and preparation products, and IV fluids.

BD has a strong presence throughout Eastern Europe, the Middle East, and Africa regions with technical specialists, sales specialists, technical service, and application support for its products. The company distributes its products in North America (Canada, Mexico, and the US), Europe (Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Netherland, Poland, Switzerland, Russia, United Kingdom, Turkey, Hungary, Italy), South America (Argentina, Brazil, Chile, and Colombia), Asia-Pacific (Australia, New Zealand, Indonesia, Korea, Malaysia, Philippines, Thailand, and Vietnam) and the Middle East and Africa (the Middle East, North Africa, and Africa).

Strategy

Becton, Dickinson and Company focuses to achieve growth by expanding its product portfolio and geographic reach through both organic growth and acquisitions. The company is investing heavily in research and development to develop new products and technologies that can improve patient outcomes and reduce healthcare costs. In addition, Becton, Dickinson and Company is focused on expanding its market share in emerging markets with increasing healthcare needs, such as Asia and Latin America. The company is also pursuing strategic partnerships and collaborations to leverage complementary capabilities and expand its market reach, with a focus on expanding its presence in the oncology and immunology spaces.

Company Snapshot

$16,074M

Revenue

65,000

Employees

1897

Founded

New Jersey, US

Headquarters

SWOT Analysis

Strengths

Competitive products with a solid sales growth outlook
Strong cost controls
Well established distribution channel
Focused research and development capabilities
Market leadership
Improved performance of the laboratory products and services segment
Strong research and development capabilities High market share Improved performance of its laboratory products and services segment
Strong research and development capabilities
Improved performance of its laboratory products and services segment
Improved performance of laboratory products and the services segment
Strong research and development capabilities High market share
Strong R&D capabilities
Diversified manufacturing operations globally
Highly successful at ‘go to market strategies’ for its products
Accelerated strategic efforts to simplify network, portfolio, and processes
Strong brand recognition and a diversified product portfolio in the medical technology and healthcare sectors.

Weaknesses

Large amount of international sales causes fluctuating currency exchange rates to have a material impact on growth
Involvement in patent infringement litigation ruining the brand image
Increasing debt burden
Patent infringement and other disputes
Increasing debt burden Patent infringement and other legal disputes
Patent infringement and other legal disputes
Increasing liabilities
Increasing debt burden and gaps in the product range sold by the company
High dependence on a limited number of large customers, which may increase risk and limit growth opportunities.

Opportunities

International growth for the medical supplies industry
Emerging markets operations
New product launches
Inorganic growth initiatives
New products and services
Agreements and collaborations
Partnerships and collaborations for product line expansion
Global in-vitro diagnostic market
Rising partnerships and collaborations for product line expansion
Introduction of new technology by the company provides an opportunity to practice differentiated pricing strategy in the market
Stable free cash flow of the company is providing opportunities to invest in adjacent product segments
Growing demand for medical technologies, especially in emerging markets with increasing healthcare needs.
Expansion into new product categories and therapeutic areas, such as oncology and immunology.

Threats

Alliance of intensify competition
Fluctuating economies
Government regulations on medical devices
Competitive environment
Rapid technological changes
Regulatory environment
High competition Rapid technological changes Changing regulatory environment
High competition
Changing regulatory environment
Downturn in global economic conditions adversely affects the company’s operations
Competitive environment
Rising raw material prices
Fluctuating economy due to COVID-19
Changing regulatory scenario
Intense competition from other medical technology companies in the global market.
Changes in regulatory policies or reimbursement environment, which may affect the demand and pricing for the company's products and services.

Key Developments

Date	Approach	Development
March 2015	Acquisition	Completed the acquisition of CareFusion Corporation (CareFusion) for $12.2 billion. CareFusion will operate as a wholly-owned subsidiary of BD. The acquisition is intended to enhance the medication management and patient safety solutions provided by BD.
March 2015	Acquisition	Announced the acquisition of CRISI Medical Systems, a medical technology company focused on providing safety and delivery of IV injectable medications. The acquisition will strengthen BD’s position in addressing preventable medication errors and improve care delivery efficiencies.
October 2014	Acquisition	Announced the acquisition of GenCellBio systems, an Irish biotech company that has developed proprietary technologies that address key biological analysis protocols, for an undisclosed consideration. The acquisition is expected to improve the BD’s Next Generation Sequencing line of products.
December 2017	Acquisition	BD acquired C. R. Bard, Inc. for USD 24 billion. With this acquisition, the company aimed to become a leader in the healthcare industry. This acquisition made BD generate annual revenue of approximately USD 16 billion in 2017.
July 2017	Product Launch	BD launched new technology (BD Kiestra urine culture app) to automatically report and release negative urine cultures. The BD Kiestra urine culture app will integrate with BD BBL plated media to determine the growth of the urine sample. The BD Kiestra urine culture app can also be used for work cell automation and total lab automation solution. This product launch will aid the company in enhancing its microbiology portfolio.
–	Investment	Becton, Dickinson, and Company announced an investment of USD 24 million from the US department of defense in collaboration with the US department of Health and Human Services to provide support for the scale up of US manufacturing facilities for BD Veritor solution for rapid detection of SARS-CoV-2
November-2022	Expansion	Government representatives from Mexico and Baja California joined BD (Becton, Dickinson and Company), a major global provider of medical technology, to officially open a new $38.6 million manufacturing facility in Tijuana that will create tools and innovations that enhance medication safety in healthcare settings.
May-2022	Partnership	A strategic alliance between BD (Becton, Dickinson and Company), a major worldwide medical technology firm, and Babson Diagnostics, a science-first health care technology company, has expanded. This will allow patients to obtain blood samples at home for diagnostic testing.

Product Offering

Becton, Dickinson and Company
- Peripheral Vascular
- Peripheral Stent
- Swabs
- Autoinjector
- CHG Cloth
- Immunoassay products
- Bead-based Immunoassay
- BD ELISA Reagents
- BD ELISPOT Reagents
- Cell Culture Tools
- Culture Media
- Reagents
- Safety Lancet
- Closed Vial Access Devices
- Closed Syringe Safety Devices
- Closed Bag/Line Access Devices
- BD Medical
- Lab automation
- Global Immunoassays In R&D Market
- Breast Biopsy Products

Financial Performance

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.